HSF1A |
Catalog No.GC32437
One-Click Copy Product Info
|
HSF1A es un activador del Heat Shock Transcription Factor 1 (HSF1)
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1196723-93-9
Sample solution is provided at 25 µL, 10mM.
HSF1A es un activador del Heat Shock Transcription Factor 1 (HSF1) [1]. HSF1A inhibe la actividad de la chaperona molecular TRiC/CCT, activando así HSF1 y mejorando la resistencia celular al mal plegado de proteínas y al estrés [2-3]. HSF1A se utiliza principalmente para tratar enfermedades neurodegenerativas [4].
En las células madre hematopoyéticas (HSCs) de CD150+CD48-LSK, HSF1A (8μM; 10d) mejora la actividad reconstitutiva en serie de los HSCs cultivados in vitro [5]. En las células de ovario de hámster chino, HSF1A (200µM; 1h) protege las células de la citotoxicidad inducida por la toxina de la pertussis [6].
En ratas wistar lyoto, HSF1A (100mg/kg; ip; 4 semanas) mejora la insuficiencia cardíaca inducida por doxorrubicina in vivo [7]. En el modelo de ratones de asma alérgico inducido por ovalbúmina, el tratamiento con HSF1A (1.3g/kg; ig; 5 semanas) no solo reduce la inflamación y el estrés oxidativo, sino que también atenúa significativamente la fibrosis de las vías respiratorias[8].
References:
[1]. Neef D W, Jaeger A M, Gomez-Pastor R, et al. A direct regulatory interaction between chaperonin TRiC and stress-responsive transcription factor HSF1[J]. Cell reports, 2014, 9(3): 955-966.
[2]. Neef D W, Turski M L, Thiele D J. Modulation of heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease[J]. PLoS biology, 2010, 8(1): e1000291.
[3]. Steinemann M, Schlosser A, Jank T, et al. The chaperonin TRiC/CCT is essential for the action of bacterial glycosylating protein toxins like Clostridium difficile toxins A and B[J]. Proceedings of the National Academy of Sciences, 2018, 115(38): 9580-9585.
[4]. Liu A Y, Minetti C A, Remeta D P, et al. HSF1, aging, and neurodegeneration[J]. Cell Biology and Translational Medicine, Volume 18: Tissue Differentiation, Repair in Health and Disease, 2022: 23-49.
[5]. Kruta M, Sunshine M J, Chua B A, et al. Hsf1 promotes hematopoietic stem cell fitness and proteostasis in response to ex vivo culture stress and aging[J]. Cell stem cell, 2021, 28(11): 1950-1965. e6.
[6]. Jia J, Zoeschg M, Barth H, et al. The chaperonin TRiC/CCT inhibitor HSF1A protects cells from intoxication with pertussis toxin[J]. Toxins, 2024, 16(1): 36.
[7]. Huang C Y, Kuo W W, Lo J F, et al. Doxorubicin attenuates CHIP-guarded HSF1 nuclear translocation and protein stability to trigger IGF-IIR-dependent cardiomyocyte death[J]. Cell death & disease, 2016, 7(11): e2455-e2455.
[8]. Liu X, Zhang Y, Wu H, et al. HSF1 in macrophages suppressed the progression of asthma via modulating SIRPα/SHP2—Dectin-1/SYK mediated ROS and inflammatory responses[J]. Scientific Reports, 2025, 15(1): 29741.
| Experimentos celulares [1]: | |
Líneas celulares | Células madre hematopoyéticas CD150+CD48-LSK (HSC) |
Método de preparación | Los HSC CD150+CD48-LSK se clasificaron de la médula ósea de ratones adultos jóvenes directamente en placas de fondo en V de 96 pozos a una densidad de 10 células/pocillo que contenía medio de cultivo de HSC básico recién hecho (medio de células hematopoyéticas de ratón Prime-XV) con SCF (50 ng/ml), TPO (50ng/ml), 2-Mercaptoetanol (50 μM) y albúmina de suero bovino (BSA; 0,1%). Cuando se especificó, el medio HSC básico se suplementó con 17-AAG (5nM) o HSF1A (8μM) en 0,02 % de DMSO. Como control, el medio HSC básico se complementó con DMSO al 0,02 %. |
Condiciones de reacción | 8μM; 10d |
Áreas de aplicación | HSF1A mejora la actividad reconstitutiva en serie de los HSC cultivados in vitro. |
| Experimentos con animales [2]: | |
Modelos animales | Ratos Wistar Kyoto |
Método de preparación | Se utilizaron ratas Wistar Kyoto (WKY) de diez semanas de edad. Las ratas fueron alojadas a una temperatura constante (22℃) con un ciclo de luz/oscuridad de 12 horas y se les proporcionó comida y agua del grifo. Los animales se dividieron en tres grupos: ratas WKY (grupo de control), ratas de doxorrubicina (DOX) y ratas DOX tratadas con HSF1A. Cada grupo contenía cinco animales. El grupo DOX recibió inyecciones intraperitoneales de DOX (5 mg/kg) durante 6 semanas consecutivas, alcanzando una dosis acumulada de 30 mg/kg, que ha demostrado ser cardiotóxico. HSF1A, un activador de HSF1 de molécula pequeña, también se administró por vía intraperitoneal (100 mg/kg/día). |
Forma de dosificación | 100 mg/kg; ip; 4 semanas |
Áreas de aplicación | HSF1A mejora la insuficiencia cardíaca inducida por doxorrubicina in vivo. |
References: | |
| Cas No. | 1196723-93-9 | SDF | |
| Canonical SMILES | O=S(C1=CC=C(CC)C=C1)(NC2=CC(C3=CC=CS3)=NN2C4=CC=CC=C4)=O | ||
| Formula | C21H19N3O2S2 | M.Wt | 409.52 |
| Solubility | DMSO : ≥ 150 mg/mL (366.28 mM);Water : < 0.1 mg/mL (insoluble) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4419 mL | 12.2094 mL | 24.4188 mL |
| 5 mM | 488.4 μL | 2.4419 mL | 4.8838 mL |
| 10 mM | 244.2 μL | 1.2209 mL | 2.4419 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)